Incyte Stock Forecast for 2023 - 2025 - 2030
Updated on 03/29/2024
Incyte Stock Forecast and Price Target
If the average 2024 price target of $77.20 recently set by eight prominent experts for Incyte is met, there would be a potential upside of approximately 26.99% from the last closing price in March, 2024. The high estimate is $92.00, and the low is $58.00. If you are interested in INCY stock, you should also look at its competitors.
26.99% Upside
Incyte Fair Value Forecast for 2023 - 2025 - 2030
Incyte's Price has seen impressive growth In the last four years, rising from $0.00 to $0.00 – a growth of 100.00%. In the next year, analysts believe that Fair Value will reach $146.11 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
ABBV Stock Forecast | AbbVie | Outperform |
9
|
$179.63 | Buy/Sell | $178.42 | 0.21% |
MRK Stock Forecast | Merck | Outperform |
2
|
$122.77 | Buy/Sell | $130.51 | 9.96% |
ROG Stock Forecast | Roche Holding | Hold |
16
|
CHF242.00 | Buy/Sell | CHF307.83 | 11.57% |
AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£104.50 | Buy/Sell | £165.99 | 53.79% |
NOVN Stock Forecast | Novartis | Outperform |
10
|
CHF88.80 | Buy/Sell | CHF105.00 | 23.95% |
Incyte Revenue Forecast for 2023 - 2025 - 2030
Incyte's Revenue has seen impressive growth In the last three years, rising from $2.67B to $3.70B – a growth of 38.59%. In the next year, analysts believe that Revenue will reach $4.53B – an increase of 22.63%. For the next seven years, the forecast is for Revenue to grow by 6.72%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
AMGN Stock Forecast | Amgen | Outperform |
4
|
$275.36 | Buy/Sell | $303.65 | 14.40% |
SAN Stock Forecast | Sanofi | Outperform |
16
|
88.32€ | Buy/Sell | 102.80€ | 21.15% |
BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$54.36 | Buy/Sell | $58.15 | 1.18% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$964.44 | Buy/Sell | $961.26 | 8.87% |
GSK Stock Forecast | GSK | Outperform |
12
|
£16.75 | Buy/Sell | £17.30 | 11.04% |
MRK Stock Forecast | Merck KGaA | Outperform |
18
|
156.75€ | Buy/Sell | 190.06€ | 9.73% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
5
|
¥4.31k | Buy/Sell | ¥4.74k | 6.63% |
4523 Stock Forecast | Eisai | Outperform |
18
|
¥6.37k | Buy/Sell | ¥9.58k | 31.83% |
JAZZ Stock Forecast | Jazz Pharmaceuticals | Outperform |
14
|
$116.63 | Buy/Sell | $188.32 | 59.52% |
Incyte EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Incyte's EBITDA has seen an increase, rising from $-187.53M to $738.52M. This represents a growth of 493.81%. Analysts predict that Incyte's EBITDA will increase in the upcoming year, reaching $1.82B. This would represent an increase of 146.37%. Over the next seven years, experts predict that Incyte's EBITDA will grow at a rate of 241.22%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
APLS Stock Forecast | Apellis Pharmaceuticals | Outperform |
6
|
$60.69 | Buy/Sell | $71.19 | 38.41% |
IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$43.26 | Buy/Sell | $55.60 | 41.01% |
EXEL Stock Forecast | Exelixis | Outperform |
16
|
$22.46 | Buy/Sell | $26.44 | 20.21% |
Incyte EBIT Forecast for 2023 - 2025 - 2030
Incyte's EBIT has seen growth In the last three years, going from $-241.24M to $652.36M – a gain of 370.42% In the next year, analysts believe that EBIT will reach $1.45B – an increase of 122.10%. For the next seven years, the forecast is forEBIT to grow by 102.04%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
MOR Stock Forecast | MorphoSys | Outperform |
6
|
65.52€ | Buy/Sell | 28.78€ | 3.79% |
GERN Stock Forecast | Geron | Buy |
6
|
$2.14 | Buy/Sell | $4.83 | 121.96% |
PGEN Stock Forecast | Precigen | Outperform |
8
|
$1.56 | Buy/Sell | $9.46 | 348.72% |
Incyte EPS Price Prediction Forecast for 2023 - 2025 - 2030
Incyte's EPS has seen impressive growth In the last four years, rising from $-0.42 to $0.00 – a growth of 100.00%. In the next year, analysts believe that EPS will reach $6.05 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
OMER Stock Forecast | Omeros | Hold |
11
|
$4.20 | Buy/Sell | $13.00 | -100.00% |
XFOR Stock Forecast | X4 Pharmaceuticals | Outperform |
4
|
$0.91 | Buy/Sell | $3.26 | 229.67% |
KPTI Stock Forecast | Karyopharm Therapeutics | Outperform |
6
|
$1.48 | Buy/Sell | $6.00 | 237.84% |